Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.55
-0.64 (-6.28%)
At close: Apr 1, 2025, 4:00 PM
9.53
-0.02 (-0.19%)
After-hours: Apr 1, 2025, 5:16 PM EDT

Keros Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Net Income
-187.35-152.99-104.68-58.74-45.36
Upgrade
Depreciation & Amortization
1.230.820.670.380.28
Upgrade
Loss (Gain) From Sale of Assets
-00.010.05-
Upgrade
Stock-Based Compensation
34.8728.7618.6811.724.1
Upgrade
Other Operating Activities
1.821.550.940.521.82
Upgrade
Change in Accounts Receivable
-2.6-0.1418-18-
Upgrade
Change in Accounts Payable
-0.251.61-0.411.490.06
Upgrade
Change in Other Net Operating Assets
-8.59-4.12-3.280.452.21
Upgrade
Operating Cash Flow
-160.87-124.51-70.06-62.15-36.89
Upgrade
Capital Expenditures
-1.93-2.46-1.24-1.02-0.29
Upgrade
Investing Cash Flow
-1.93-2.46-1.24-1.02-0.29
Upgrade
Issuance of Common Stock
392.28179.05120.428.55259.94
Upgrade
Other Financing Activities
-0.45-0.09-0.09--19.89
Upgrade
Financing Cash Flow
391.82178.96120.3128.55296.04
Upgrade
Net Cash Flow
229.0251.9849.01-34.62258.86
Upgrade
Free Cash Flow
-162.8-126.97-71.3-63.17-37.19
Upgrade
Free Cash Flow Margin
-4585.91%-84087.42%--314.29%-
Upgrade
Free Cash Flow Per Share
-4.35-4.31-2.83-2.71-2.40
Upgrade
Levered Free Cash Flow
-108.31-81.25-33.84-39.48-22.38
Upgrade
Unlevered Free Cash Flow
-108.31-81.25-33.84-39.48-22.37
Upgrade
Change in Net Working Capital
10.712.15-19.7915.33-2.71
Upgrade
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q